Life Science Investing Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
Life Science Investing Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
Life Science Investing Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
Life Science Investing Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria and Chronic Kidney Disease
Real-World Uranium Markets Meet DeFi with the Launch of xU3O8-Based Lending on Oku, Powered by Morpho
